784 research outputs found
Replication Data for "Circulating Fibroblast Activation Protein as Potential Biomarker in Patients With Inflammatory Bowel Disease"
No full textThis dataset contains raw data contained in the manuscripit "Circulating Fibroblast Activation Protein as potential diagnostic and mucosal healing biomarker in patients with Inflammatory Bowel Diseases." by Fabio Corsi, Luca Sorrentino, Sara Albasini, Francesco Colombo, Maria Cigognini, Alessandro Massari, Carlo Morasso, Serena Mazzucchelli, Francesca Piccotti, Sandro Ardizzone, Gianluca M Sampietro, Marta Truffi
Replication Data for Selective Targeting of Cancer-Associated Fibroblasts by Engineered H-Ferritin Nanocages Loaded with Navitoclax
No full textThis dataset contains raw data from Sitia, L.; Bonizzi, A.; Mazzucchelli, S.; Negri, S.; Sottani, C.; Grignani, E.; Rizzuto, M.A.; Prosperi, D.; Sorren-tino, L.; Morasso, C.; et al. Selective targeting of Cancer-Associated Fi-broblasts by engineered H-ferritin nanocages loaded with navitoclax. Cells 2021, 10.3390/cells1002032
Replication Data for Breast Cancer Patient-derived Organoids as case study for the investigation of patient’s specific tumour evolution
No full textThis dataset contains raw data of results published in Mazzucchelli S. et al. "Breast Cancer Patient-derived Organoids as case study for the investigation of patient’s specific tumour evolution".
This dataset reports a case-study of breast cancer patient-derived organoid (PDO). Here, PDO were collected from the same patient after diagnostic biopsy and after the neoadjuvant chemotherapy allowing us to study the tumor evolution. The dataset contains three tabular files, as indicated in the 'Notes' field
Redesigning human ferritin nanocages for therapeutic applications: from cancer treatment to hypercholesterolemia management
No full textProtein-based nanoparticles are increasingly significant in nanomedicine due to their biocompatibility, specificity, and modifiability, offering innovative solutions to therapeutic challenges. Among these, human ferritin stands out for its versatility. Its hollow structure, along with the ability to modify both internal and external surfaces chemically or genetically, makes it an ideal candidate for a variety of applications, including targeted drug delivery, molecular imaging, immunotherapy, and vaccine development. Given these unique properties, this Ph.D. research explores the potential of human H ferritin (HFn) by modifying its surfaces for two distinct biomedical applications. The first objective focuses on enhancing ferritin’s ability to encapsulate hydrophobic drugs, addressing a major limitation in drug delivery systems. By incorporating four or six tryptophan residues per subunit, oriented towards the nanoparticle’s internal cavity, we increased its hydrophobicity, with the aim to improve its capacity to encapsulate hydrophobic chemotherapeutic agents. Detailed characterization revealed that only the variant with four tryptophan residues per subunit retained the ability to disassemble and reassemble correctly. To demonstrate the potential of this modification, we tested the loading capacity of this mutant with ellipticine, a natural hydrophobic indole alkaloid with anticancer properties. Our findings showed that this mutant was far more efficient at loading ellipticine compared to wild-type ferritin. We further evaluated the versatility of this nanoparticle by also encapsulating doxorubicin, a commonly used anticancer drug. Both ellipticine- and doxorubicin-loaded nanoparticles were tested on a promyelocytic leukemia cell line, where efficient drug uptake by the cells and the expected cytotoxic effects were observed. The second objective targets hypercholesterolemia, a major risk factor for cardiovascular disease, by focusing on Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), a protein that regulates cholesterol levels. PCSK9 decreases the number of LDL receptors on liver cells by promoting their degradation, impairing the clearance of LDL cholesterol from the bloodstream. To counteract this, HFn was genetically modified to display 24 copies of a 13-amino acid peptide (Pep2-8) on its surface, previously identified as the smallest PCSK9 inhibitor. Biochemical analysis confirmed precise control over nanoparticle size and morphology, as well as strong PCSK9-binding affinity in the high picomolar range. Functional studies in HepG2 liver cells showed enhanced LDL receptor recycling and LDL uptake, confirming the effectiveness of this multivalent nanoparticle in promoting cholesterol clearance. Together, these findings highlight the multifunctional nature of human H ferritin, making it as a promising platform that can be tailored for diverse therapeutic interventions, from targeted cancer treatment to the modulation of critical physiological pathways in various diseases. The ability to engineer ferritin nanoparticles to display different peptides or proteins further expands its versatility, opening avenues for the development of multifunctional therapeutics with the potential to target multiple pathways simultaneously
Replication Data for Ferritin nanoconjugates guide trastuzumab brain delivery to promote an antitumor response in murine HER2 + breast cancer brain metastasis
No full textThis dataset contains raw data of the paper " Ferritin nanoconjugates guide trastuzumab brain delivery to promote an antitumor response in murine HER2+ breast cancer brain metastasis" by Sevieri M. et al.
Brain metastasis (BM) represents a clinical challenge for patients with advanced HER2 + breast cancer (BC). The monoclonal anti-HER2 antibody trastuzumab (TZ) improves survival of BC patients, but it has low central nervous system penetrance, being ineffective in treating BM. Previous studies showed that ferritin nanoparticles (HFn) may cross the blood brain barrier (BBB) through binding to the transferrin receptor 1 (TfR1). However, whether this has efficacy in promoting the trans-BBB delivery of TZ and combating BC BM was not studied yet. Here, we investigated the potential of HFn to drive TZ brain delivery and promote a targeted antitumor response in a murine model of BC BM established by stereotaxic injection of engineered BC cells overexpressing human HER2. HFn were covalently conjugated with TZ to obtain a nanoconjugate endowed with HER2 and TfR1 targeting specificity (H-TZ). H-TZ efficiently achieved TZ brain delivery upon intraperitoneal injection and triggered stable targeting of cancer cells. Treatment with H-TZ plus docetaxel significantly reduced tumor growth and shaped a protective brain microenvironment by engaging macrophage activation toward cancer cells. H-TZ-based treatment also avoided TZ-associated cardiotoxicity by preventing drug accumulation in the heart and did not induce any other major side effects when combined with docetaxel. These results provided in vivo demonstration of the pharmacological potential of H-TZ, able to tackle BC BM in combination with docetaxel. Indeed, upon systemic administration, the nanoconjugate guides TZ brain accumulation, reduces BM growth and limits side effects in off-target organs, thus showing promise for the management of HER2 + BC metastatic to the brain
Replication data for "Surface functionalization with short PAS-sequence affects H-Ferritin nanocage stability"
No full textThis file contains the raw data used to produce the manuscript "Surface functionalization with short PAS-sequence affects H-ferritin nanocage stability" by Tagliolini I. et al. The scope of the work is to investigate the impact of shorter PAS domains on the stability of HFn, focusing on a mutant modified with 20 amino acids PAS domains. Indeed, this mutant was successfully produced and purified but seems unable to form a stable quaternary structure. Here, we studied the structural dynamics properties of native HFn, PAS20-HFn, PAS40-HFn dimers, tetramers, and octamers. Our simulations indicate that PAS20-HFn tetramers exhibit increased flexibility in a specific region that is critical for dimer interactions and organization of higher-order complexes. This highlights the bipolar and essential role of HFn PASylation in HFn nanocages, especially concerning their size. Please refer to the related publication for details about the methodology of data collection and analysis. All data were loaded in a single file, in nine separate sheets (each related to a specific figure or table in the manuscript)
Replication Data for Combined Method to Remove Endotoxins from Protein Nanocages for Drug Delivery Applications: The Case of Human Ferritin
No full textThis dataset contains raw data from the publication Silva F. et al. Combined method to remove endotoxins from protein nanocages for drug delivery applications: the case of human ferritin. Pharmaceutics 2021, 13, doi: 10.3390/pharmaceutics1302022
Replication Data for: "H-ferritin nanocages: refined strategy for optimized protein production and purification"
No full textThis dataset aims to collect all raw data published in the manuscript "H-ferritin nanocages: refined strategy for optimized protein production and purification" by Bonizzi A. et al. The scope of the work is to compare two lysis methods and purification protocols using the Clear coli BL21(DE3) strain as a source of HFn nanocages. Please refer to the related publication for details about the methodology of data collection and analysis. All data were loaded in a single file, in seven separate sheets (each related to a specific table or figure in the manuscript)
Replication Data for "Deciphering the role of H-ferritin nanocages in improving tumor-targeted delivery of Indocyanine Green: combined analysis of murine tissue homogenates with UHPLC-MS/MS and fluorescence"
No full textThis dataset contains raw data of results published in Sevieri M. et al. "Deciphering the role of H-ferritin nanocages in improving tumor-targeted delivery of Indocyanine Green: combined analysis of murine tissue homogenates with UHPLC-MS/MS and fluorescence
Replication Data for "Tumor Accumulation and Off-Target Biodistribution of an Indocyanine-Green Fluorescent Nanotracer: An Ex Vivo Study on an Orthotopic Murine Model of Breast Cancer"
No full textContains the results published in Sevieri M. et al. 2021, Int. J Mol. Science
- …
